Condition: Respiratory Distress Syndrome, Adult · Sponsor: BioMarck Pharmaceuticals, Ltd.
This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The treatment will continue for up to 28 days. The study will enroll up to 40 adult ARDS patients in up to eight sites within USA.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Chicago Medicine | Chicago, Illinois, United States | — |
| University of North Carolina School of Medicine | Chapel Hill, North Carolina, United States | — |
| Wake Forest University | Winston-Salem, North Carolina, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| Vanderbilt University, Div of Allergy, Pulmonary, Critical Care | Nashville, Tennessee, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03202394